CA-CIRCLECI
14.3.2024 14:01:34 CET | Business Wire | Press release
CircleCI, the leading continuous integration and continuous delivery (CI/CD) platform, today unveiled CircleCI releases, which enables developers to automate the release orchestration process directly from the CircleCI UI. With current support for Kubernetes and Amazon SageMaker, developers now have end-to-end visibility of their deployments in production and access to rollback commands (e.g., restore version, scale component, and restart component) for seamless release management. CircleCI releases makes deploying code less risky, user-focused, and more accessible for developers to ship faster with confidence.
Today, developers operate in increasingly complex tech stacks yet are under pressure to move quickly without compromising software quality. As a result, elite engineering teams are incorporating agile development practices like progressive delivery and canary releases, which provide the guardrails necessary for risk-free deployments via the ability to target, segment, and roll back releases. CircleCI releases enables software teams to automate the progressive delivery process with support for Argo Rollouts, giving developers complete control over their releases. Future support for blue-green deployments is slated for later in 2024. By automating CI/CD pipelines directly into the release orchestration process, software teams dramatically reduce mean-time-to-recovery (MTTR), giving them the confidence to resolve issues should releases go awry with little to no impact on their customers.
Key features and benefits of CircleCI releases include:
- Change validation: Developers can validate the entire change from build to production.
- User-focused releases and minimized risk: Developers can connect their CI/CD pipeline directly to the customer experience to make releases user-focused, risk-free, and rollback-friendly.
- Increased code confidence: With automated release orchestration, teams will definitively know that their code is working as intended.
- Automated rollbacks: Manual rollbacks take 45 minutes to an hour. Automated rollbacks make the delivery process fast, efficient, and streamlined.
- Real-time service validation: Developers can safely release code to a controlled subset of real users in a live production environment to get immediate feedback on how code performs. Flexible subsets include internal testers, beta customers, or an external low-risk customer group of choice.
- Performance degradation prevention: Automate your release conditions and best practices into a release policy to act as guardrails. By automating software validation in production and rolling back releases when necessary, developers, operators, and customers are protected from performance degradation.
“If you look at every other deploy and release vendor on the market, they’re built to service centralized release and operations teams who want tighter control over deploys,” said Rob Zuber, CTO of CircleCI. “But this doesn’t reflect the reality of elite software teams who depend on developers to drive and deliver fast innovation. Our approach to CircleCI releases provides a developer-centric workflow that enables them to ship faster and monitor new features in production coupled with the safety net of quickly rolling back releases if something goes wrong.”
CircleCI releases is now available to all CircleCI users. To learn more or chat about how CircleCI can empower your team to deliver innovation faster, visit one of our experts at KubeCon EU, booth M16 from March 19-21, 2024. Get started using CircleCI releases today.
About CircleCI
CircleCI is a leading continuous integration and continuous delivery (CI/CD) platform, enabling more than two million global users on elite engineering teams like Okta, Hinge, and Hugging Face to rapidly build, test, deploy, and monitor software they can trust. Through powerful pipeline automation, CircleCI manages limitless complexity at scale through unmatched flexibility and reliability, reducing the time from build to delivery by 3x the industry average. For more information about CircleCI, visit www.circleci.com or follow us on Twitter, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314509917/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom